- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03684707
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomised Clinical Trial
Evaluation of the metformin drug effect as a drug that found to improve the quality of tissues, decrease signs & symptoms of cancer, and decrease histo-pathological criteria of dysplasia.
This will be done by the aid of measuring salivary Micro RNA 31 & 210 in saliva in addition to measure cyclin A2 as an immuno-histochemical analysis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Oral squamous cell carcinomas (OSCCs) are among the most common types of head and neck cancers and are a major cause of significant morbidity. It was reported that 16- 62% of OSCCs develop from premalignant lesions, which often presents clinically as white or red mucosal patches known as leukoplakia and erythroplakia. The role of miRNA in cancer has been reiterated and established by many studies that have shown that miRNA signatures (i.e., mRNA expression profiles) can be useful for classifying human cancers. These studies have identified "cancer related miRNAs" through investigating expression profiles in matched normal and tumor tissues, as well as in body fluids. In addition, a vast number of studies have shown that miRNAs can play a role in regulating the expression of oncogenes and tumor suppressor genes, whereas others have shown that miRNA gene deletion or mutation can lead cancer initiation, progression and metastasis . Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth in vitro and vivo:
(1) Activation of LKB1/AMPK pathway, (2) Induction of cell cycle arrest and/or apoptosis, (3) Inhibition of protein synthesis, (4) Reduction in circulating insulin levels, (5) Inhibition of the unfolded protein response (UPR), (6) Activation of the immune system.
This study is performed to evaluate metformin effect on the patients premalignant lesion versus maintenace follow ups.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Noha N. El-Zalabany, Masters
- Phone Number: 02 01005365769
- Email: noha_nasr84@yahoo.com
Study Contact Backup
- Name: Ahmed A. Abd El-Azim, Masters
- Phone Number: 02 01007975679
- Email: hero_ahmed704@hotmail.com
Study Locations
-
-
New Cairo
-
Cairo, New Cairo, Egypt, 11835
- Recruiting
- Noha Nasr
-
Contact:
- Noha N. El-Zalabany, Masters
- Phone Number: 02 01005365769
- Email: noha_nasr84@yahoo.com
-
Contact:
- Noha N. El-Zalabany, Masters
- Phone Number: 02 1005365769
- Email: noha_nasr84@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Both genders with age range from 20 to 70 years.
- Patients able to return for the follow up visits and can perform oral hygiene measures.
- Clinically diagnosed and histologically confirmed as having oral potentially malignant lesions.
- Patients agreed to sign a written consent after understanding the nature of the study
- Patients have diagnosed oral premalignant lesion/lesions and not yet turned into malignancy (atrophic lichen planus- leukoplakia-erythroplakia - oral submucous fibrosis)
Exclusion Criteria:
- - Diabetic patients (Diabetes Mellitus Type I & II)
- Patients have cardiovascular, lung, Renal, Liver diseases
- Patients on H2 blocker & proton pump inhibitors therapy as Ranitidine (affects metformin absorption and clearance)
- Those with allergy or sensitivity to Metformin or Retinoids therapy or having any contraindication for their use.
- Systemic and/or local systemic drug therapy within the last 3 months prior to the start of the study
- Patients on steroidal or Non-steroidal anti-inflammatory drugs (NSAIDs) for at least the last 6 months
- Patients on Antibiotics treatment for at least the last 2 months
- Patients on Retinoid, green tea supplements or another natural products therapy
- Patients with already diagnosed malignant lesion/lesions
- Pregnant or Lactating females
- Vulnerable groups as prisoners, mentally disabled, etc…
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Metformin Hcl 500Mg 24Hr Sa Tab
Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient
|
Glucophage 500 mg once daily
Other Names:
|
Placebo Comparator: control
starch tablets
|
starch tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate lesion size in millimeters
Time Frame: 1 year
|
Evaluate lesion size in millimeters
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of salivary Micro RNA
Time Frame: 1 year
|
measuring salivary markers 31& 210 in saliva and also in tissue biopsy
|
1 year
|
Measuring immuno-histochemical marker
Time Frame: 1 year
|
Measuring cyclin A2 marker in tissues
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Fathia Z. Zahran, PHD, Cairo University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- cairo university (Other Grant/Funding Number: faculty of pedatric dentistry)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Cancer
-
Royal Surrey County Hospital NHS Foundation TrustCompleted
-
Centre Francois BaclesseTerminatedCancer | Cognitive Function | Compliance | Oral TherapiesFrance
-
University of WashingtonBlaze Bioscience Inc.RecruitingStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Oral LeukoplakiaUnited States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States
-
Dana-Farber Cancer InstituteCompletedBreast Cancer | Gastrointestinal Cancer | Oral Cancer Directed Therapy | Oral ChemotherapyUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma | Stage 0 Lip and Oral Cavity CancerUnited States
-
University of British ColumbiaRecruiting
-
Istituto Scientifico Romagnolo per lo Studio e...Kessler FoundationUnknownCancer | Oral Drug AdministrationItaly
-
Centre Francois BaclesseLigue contre le cancer, FranceCompletedManagement of Oral Care and Cancer in Palliative SituationFrance
Clinical Trials on Metformin Hcl 500Mg 24Hr Sa Tab
-
Tanta UniversityCompleted
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Handok Inc.Completed
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Donald MabbottRecruitingCognitive Impairment | Medulloblastoma, ChildhoodCanada, Australia
-
American University of Beirut Medical CenterRecruiting
-
LG Life SciencesCompletedType 2 DiabetesKorea, Republic of
-
Chung-Hoon KimCompletedPolycystic Ovary SyndromeKorea, Republic of